Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence

References

• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833.
   PubMed Web of Science ®Google Scholar
• Fiore J, Co-van der Mee MM, Maldonado A, Glasser L, Watson P. Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance. Ther Adv Vaccines Immunother. 2021;9:25151355211057479. doi:10.1177/25151355211057479.
   Google Scholar
• Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2):192. doi:10.3390/v14020192.
   PubMed Web of Science ®Google Scholar
• Johnson RW, Levin MJ. Herpes zoster and its prevention by vaccination. Interdiscip Top Gerontol Geriatr. 2020;43:131–22. doi:10.1159/000504484.
   PubMedGoogle Scholar
• McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020;71(7):e125–e34. doi:10.1093/cid/ciz1090.
   PubMed Web of Science ®Google Scholar
• Tavares-Da-Silva F, Co MM, Dessart C, Hervé C, López-Fauqued M, Mahaux O, Van HL, Stegmann JU. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. Vaccine. 2020;38(18):3489–500. doi:10.1016/j.vaccine.2019.11.058.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Shingrix EPAR – Product Information. Last updated 2021 Oct 13 [accessed 2022 Oct]. https://www.ema.europa.eu/documents/product-information/shingrix-epar-product-information_en.pdf.
   Google Scholar
• US Food & Drug Administration. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), suspension for intramuscular injection. Prescribing Information. Revised 2021 Jul [accessed 2022 Oct]. https://www.fda.gov/media/108597/download.
   Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–33. doi:10.1001/jama.2019.9053.
   PubMed Web of Science ®Google Scholar
• Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC . Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–87. doi:10.1093/infdis/jiu606.
   PubMed Web of Science ®Google Scholar
• Vink P, Delgado MI, Maximiano AC, Rubio-Viqueira B, Jung KH, Rodriguez MJF, Grande E, Marrupe GD, Lowndes S, Puente J, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125(8):1301–12. doi:10.1002/cncr.31909.
   PubMed Web of Science ®Google Scholar
• Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo H, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020;70(2):181–90. doi:10.1093/cid/ciz177.
   PubMed Web of Science ®Google Scholar
• Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez MG, Chiou TJ, Quiel D, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000. doi:10.1016/s1473-3099(19)30163-x.
   PubMed Web of Science ®Google Scholar
• Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, Kotton CN, Dooling KL. Use of recombinant zoster vaccine in immunocompromised adults aged ≥ 19 years: recommendations of the advisory committee on immunization practices - United States, 2022. Morb Mortal Wkly Rep. 2022;71(3):80–4. doi:10.15585/mmwr.mm7103a2.
   PubMed Web of Science ®Google Scholar
• Sturkenboom M, Bahri P, Chiucchiuini A, Grove KT, Hahné S, Khromava A, Kokki M, Kramarz P, Kurz X, Larson HJ, et al. Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines. Vaccine. 2020;38 Suppl 2():B1–B7. doi:10.1016/j.vaccine.2019.07.081.
   PubMed Web of Science ®Google Scholar
• Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study. Clin Infect Dis. 2021;73(6):949–56. doi:10.1093/cid/ciab121.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Wu X, Forshee R, Lu Y, Sung HM, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, et al. Recombinant zoster vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis. 2021;73(6):941–8. doi:10.1093/cid/ciab125.
   PubMed Web of Science ®Google Scholar
• Sun Y, Jackson K, Dalmon CA, Shapiro BL, Nie S, Wong C, Arnold BF, Porco TC, Acharya NR. Effectiveness of the recombinant zoster vaccine among Kaiser Permanente Hawaii enrollees aged 50 and older: a retrospective cohort study. Vaccine. 2021;39(29):3974–82. doi:10.1016/j.vaccine.2021.05.056.
   PubMed Web of Science ®Google Scholar
• Bruxvoort KJ, Qian L, Wu J, Florea A, Ackerson B, Sy LS, Vega DL, Takhar H, Tseng HF. Herpes zoster following recombinant zoster vaccine with or without concomitant vaccination. Open Forum Infect Dis. 2022;9(3):ofac011. doi:10.1093/ofid/ofac011.
   PubMed Web of Science ®Google Scholar
• Khan N, Wang L, Trivedi C, Pernes T, Patel M, Xie D, Yang YX. Efficacy of recombinant zoster vaccine in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2022;20(7):1570–8.e1571. doi:10.1016/j.cgh.2021.07.023.
   PubMed Web of Science ®Google Scholar
• Lu A, Sun Y, Porco TC, Arnold BF, Acharya NR. Effectiveness of the recombinant zoster vaccine for herpes zoster ophthalmicus in the United States. Ophthalmology. 2021;128(12):1699–707. doi:10.1016/j.ophtha.2021.04.017.
   PubMed Web of Science ®Google Scholar
• Baumrin E, Izaguirre NE, Bausk B, Feeley MM, Bay CP, Yang Q, Ho VT, Baden LR, Issa NC. Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation. Blood Adv. 2021;5(6):1585–93. doi:10.1182/bloodadvances.2020003749.
   PubMed Web of Science ®Google Scholar
• Mbinta JF, Nguyen BP, Awuni PMA, Paynter J, Simpson CR. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longev. 2022;3(4):e263–e75. doi:10.1016/s2666-7568(22)00039-3.
   PubMedGoogle Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–8. doi:10.15585/mmwr.mm6703a5.
   PubMed Web of Science ®Google Scholar
• Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden AC, Heineman TC. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148–54. doi:10.1016/j.vaccine.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Harpaz R. The effectiveness of recombinant zoster vaccine: observations in the wild. Clin Infect Dis. 2021;73(6):957–60. doi:10.1093/cid/ciab130.
   PubMed Web of Science ®Google Scholar
• Kong CL, Thompson RR, Porco TC, Kim E, Acharya NR. Incidence rate of herpes zoster ophthalmicus: a retrospective cohort study from 1994 through 2018. Ophthalmology. 2020;127(3):324–30. doi:10.1016/j.ophtha.2019.10.001.
   PubMed Web of Science ®Google Scholar
• Yeh CH, Chang KS, Huang SS, Tsay SL, Tsai JM, Wang YJ. Comparing prodrugs with acyclovir for treating postherpetic neuralgia among herpes zoster patients: a systematic review and meta-analysis. Healthcare (Basel). 2022;10(7):1181. doi:10.3390/healthcare10071181.
   PubMedGoogle Scholar
• Gruver C, Guthmiller KB. Postherpetic neuralgia. Treasure Island (FL): StatPearls; 2022. PMID: 29630250. https://www.ncbi.nlm.nih.gov/books/NBK493198/.
   Google Scholar
• Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatol (Oxford). 2021;60(3):1226–33. doi:10.1093/rheumatology/keaa424.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M, Godeaux O, Grupping K, Heineman TC, Fauqued ML, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis. 2017;216(11):1352–61. doi:10.1093/infdis/jix481.
   PubMed Web of Science ®Google Scholar
• Hesse EM, Shimabukuro TT, Su JR, Hibbs BF, Dooling KL, Goud R, Lewis P, Ng CS, Cano MV. Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix) – United States, October 2017–June 2018. MMWR Morb Mortal Wkly Rep. 2019;68(4):91–4. doi:10.15585/mmwr.mm6804a4.
   PubMed Web of Science ®Google Scholar
• Pirrotta P, Tavares-Da-Silva F, Co M, Lecrenier N, Hervé C, Stegmann JU. An analysis of spontaneously reported data of vesicular and bullous cutaneous eruptions occurring following vaccination with the adjuvanted recombinant zoster vaccine. Drug Saf. 2021;44(12):1341–53. doi:10.1007/s40264-021-01118-3.
   PubMed Web of Science ®Google Scholar
• Yih WK, Kulldorff M, Dashevsky I, Maro JC. A broad safety assessment of the recombinant herpes zoster vaccine. Am J Epidemiol. 2022;191(5):957–64. doi:10.1093/aje/kwac030.
   PubMed Web of Science ®Google Scholar
• Ackerson B, Qian L, Sy LS, Bruxvoort K, Wu J, Luo Y, Diaz-Decaro J, Talarico C, Tseng HF. Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older. Vaccine. 2021;39(6):926–32. doi:10.1016/j.vaccine.2020.12.076.
   PubMed Web of Science ®Google Scholar
• Barghash MH, Taimur S, Rana M, Behar J, Mancini DM. Recombinant herpes zoster vaccine after heart transplantation: a single-center experience. J Heart Lung Transplant. 2020;39(12):1501–3. doi:10.1016/j.healun.2020.09.001.
   PubMed Web of Science ®Google Scholar
• Satyam VR, Li PH, Reich J, Qazi T, Noronha A, Wasan SK, Farraye FA. Safety of recombinant zoster vaccine in patients with inflammatory bowel disease. Dig Dis Sci. 2020;65(10):2986–91. doi:10.1007/s10620-019-06016-4.
   PubMed Web of Science ®Google Scholar
• Stevens E, Weinblatt ME, Massarotti E, Griffin F, Emani S, Desai S. Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center’s experience with 400 patients. ACR Open Rheumatol. 2020;2(6):357–61. doi:10.1002/acr2.11150.
   PubMedGoogle Scholar
• Leung J, Anderson TC, Dooling K, Xie F, Curtis JR. Recombinant zoster vaccine uptake and risk of flares among older adults with immune-mediated inflammatory diseases in the US. Arthritis Rheumatol. 2022;74(11):1833–41. doi:10.1002/art.42261.
   PubMed Web of Science ®Google Scholar
• Khan N, Trivedi C, Aberra F, Pernes T, Yang YX. Safety of recombinant zoster vaccine in patients with inflammatory bowel disease. J Crohns Colitis. 2022;16(9):1505–7. doi:10.1093/ecco-jcc/jjac040.
   PubMed Web of Science ®Google Scholar
• Lenfant T, Jin Y, Kirchner E, Hajj-Ali RA, Calabrese LH, Calabrese C. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatol (Oxford). 2021;60(11):5149–57. doi:10.1093/rheumatology/keab139.
   PubMed Web of Science ®Google Scholar
• Raza S, Acharya S, Howard G, Pattanaik D. Safety of recombinant zoster vaccine in rheumatology patients. South Med J. 2022;115(2):125–8. doi:10.14423/smj.0000000000001354.
   PubMed Web of Science ®Google Scholar
• Gupta S, Arasaratnam RJ, Solow EB, Bajaj P. A medical records review study assessing safety of zoster vaccine recombinant, adjuvanted in patients with rheumatic disease. J Clin Rheumatol. 2022;28(2):e528–e31. doi:10.1097/rhu.0000000000001790.
   PubMed Web of Science ®Google Scholar
• Goud R, Lufkin B, Duffy J, Whitaker B, Wong HL, Liao J, Lo AC, Parulekar S, Agger P, Anderson SA, et al. Risk of Guillain-Barré syndrome following recombinant zoster vaccine in Medicare beneficiaries. JAMA Intern Med. 2021;181(12):1623–30. doi:10.1001/jamainternmed.2021.6227.
   PubMed Web of Science ®Google Scholar
• Yih WK, Kulldorff M, Dashevsky I, Maro JC. Sequential data-mining for adverse events after recombinant herpes zoster vaccination using the tree-based scan statistic. Am J Epidemiol. 2023;192(2):276–82. doi:10.1093/aje/kwac176.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Ulloa-Pérez E, Yu O, Cook AJ, Jackson ML, Belongia EA, Daley MF, Harpaz R, Kharbanda EO, Klein NP, et al. Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data. Am J Epidemiol. 2023;192(2):205–16. doi:10.1093/aje/kwac170.
   PubMed Web of Science ®Google Scholar
• Venerito V, Stefanizzi P, Cantarini L, Lavista M, Galeone MG, Di Lorenzo A, Iannone F, Tafuri S, Lopalco G. Immunogenicity and safety of adjuvanted recombinant zoster vaccine in rheumatoid arthritis patients on anti-cellular biologic agents or JAK inhibitors: a prospective observational study. Int J Mol Sci. 2023;24(8):6967. doi:10.3390/ijms24086967.
   Web of Science ®Google Scholar
• Bykerk VP, Shadick N, Frits M, Bingham CO 3rd, Jeffery I, Iannaccone C, Weinblatt M, Solomon DH. Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry. J Rheumatol. 2014;41(2):227–34. doi:10.3899/jrheum.121521.
   PubMed Web of Science ®Google Scholar
• Anderson TC, Leung JW, Harpaz R, Dooling KL. Risk of Guillain–Barré syndrome following herpes zoster, United States, 2010–2018. Hum Vaccin Immunother. 2021;17(12):5304–10. doi:10.1080/21645515.2021.1985890.
   PubMed Web of Science ®Google Scholar
• Haguinet F, Pirrotta P, Bauchau V. Evaluation of the potential confounding effect of shingles on the risk of Guillain-Barré syndrome after vaccination with the recombinant zoster vaccine. ISPE Annual Meeting Abstracts. 2021 [accessed 2023 Feb 2]. https://onlinelibrary.wiley.com/doi/10.1002/pds.5305.
   Google Scholar
• FDA. FDA requires a warning about Guillain-Barré syndrome (GBS) be included in the prescribing information for Shingrix. 2021 Mar 24 [accessed 2022 Dec 19]. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-warning-about-guillain-barre-syndrome-gbs-be-included-prescribing-information-shingrix.
   Google Scholar
• Janusz CB, Anderson TC, Leidner AJ, Lee GM, Dooling K, Prosser LA. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults. Hum Vaccin Immunother. 2022;18(5):2060668. doi:10.1080/21645515.2022.2060668.
   PubMed Web of Science ®Google Scholar
• Patterson BJ, Chen CC, McGuiness CB, Glasser LI, Sun K, Buck PO. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019. Hum Vaccin Immunother. 2021;17(8):2482–7. doi:10.1080/21645515.2021.1879579.
   PubMed Web of Science ®Google Scholar
• Patterson BJ, Chen CC, McGuiness CB, Ma S, Glasser LI, Sun K, Buck PO. Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: a retrospective pharmacy and medical claims analysis. J Am Pharm Assoc (2003). 2022;62(2):526–36.e510. doi:10.1016/j.japh.2021.11.010.
   PubMed Web of Science ®Google Scholar
• McGirr A, Bourgoin T, Wortzman M, Millson B, McNeil SA. An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: a retrospective database study. Vaccine. 2021;39(25):3397–403. doi:10.1016/j.vaccine.2021.04.053.
   PubMed Web of Science ®Google Scholar
• LaMori J, Feng X, Pericone CD, Mesa-Frias M, Sogbetun O, Kulczycki A. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017–2021. Vaccine. 2022;40(15):2266–73. doi:10.1016/j.vaccine.2022.03.006.
   PubMed Web of Science ®Google Scholar
• Gatwood J, Brookhart A, Kinney O, Hagemann T, Chiu CY, Ramachandran S, Hohmeier KC. Clinical nudge impact on herpes zoster vaccine series completion in pharmacies. Am J Prev Med. 2022;63(4):582–91. doi:10.1016/j.amepre.2022.04.018.
   PubMed Web of Science ®Google Scholar
• Porter AM, Fulco PP. Impact of a pharmacist-driven recombinant zoster vaccine administration program. J Am Pharm Assoc (2003). 2021;61(2):e136–e9. doi:10.1016/j.japh.2020.11.011.
   PubMed Web of Science ®Google Scholar
• Gatwood J, Brookhart A, Kinney O, Hagemann T, Chiu CY, Ramachandran S, Gravlee E, Hohmeier K. Impact of patient and provider nudges on addressing herpes zoster vaccine series completion. Vaccine. 2023;41(3):778–86. doi:10.1016/j.vaccine.2022.12.016.
   PubMed Web of Science ®Google Scholar
• Leung J, Gray EB, Anderson TC, Sharkey SM, Dooling K. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50–64 years in the United States. Vaccine. 2022;40(50):7187–90. doi:10.1016/j.vaccine.2022.10.065.
   PubMed Web of Science ®Google Scholar
• Fix J, Vielot NA, Lund JL, Weber DJ, Smith JS, Hudgens MG, Becker-Dreps S. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50–64 years old in the United States. Vaccine. 2023;41(1):49–60. doi:10.1016/j.vaccine.2022.10.076.
   PubMed Web of Science ®Google Scholar
• Tyler R, Kile S, Strain O, Kennedy CA, Foster KT. Impact of pharmacist intervention on completion of recombinant zoster vaccine series in a community pharmacy. J Am Pharm Assoc (2003). 2021;61(4s):S12–S6. doi:10.1016/j.japh.2020.09.010.
   PubMedGoogle Scholar